Linked Life Data

10987195

Source:http://linkedlifedata.com/resource/pubmed/id/10987195

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2001-2-6
pubmed:abstractText
We monitored the efficacy of therapy with clodronate, a bisphosphonate drug, in women with postmenopausal osteoporosis, using urinary immunoenzymatic assay of C-telopeptide of collagen type I, an eight amino acid fragment (collagen fragment) of the C-telopeptide of the alpha1-chain of collagen type I (EKAHDGGR). The analysis of the dynamics of collagen fragment concentrations (a marker of bone resorption) during treatment suggests the possibility of early modulation and customization of therapy based on the levels of this marker. This could enable improved control over secondary effects and side effects of clodronate therapy. Pharmacologic inhibition of bone resorption by osteoclasts could be indirectly responsible for the increase in parathyroid hormone found during treatment with clodronate. Increased levels of parathyroid hormone are probably necessary to stimulate residual osteoclast activity and are sufficient for the maintenance of calcium-phosphate homeostasis in a new pharmacologically-induced equilibrium. Outside this context the levels of parathyroid hormone of certain patients would be considered pathologic.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1434-6621
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
489-93
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Levels of C-telopeptide fragments of collagen type I enable the monitoring and early adjustment of clodronate therapy in patients with postmenopausal osteoporosis.
pubmed:affiliation
Laboratorio di Patologia Clinica, Ospedale Geriatrico di Padova, Italy.
pubmed:publicationType
Journal Article